How India Exports Ephedrine to the World

In the United States, ephedrine is regulated by the Food and Drug Administration (FDA) and is subject to stringent controls due to its potential for misuse. The FDA has issued Import Alert 54-13, titled "Detention Without Physical Examination of Dietary Supplements And Bulk Dietary Ingredients Containing Ephedrine Alkaloids From All Countries," effective since February 21, 2025. This alert allows for the detention of such products without physical examination, underscoring the FDA's commitment to preventing the entry of potentially harmful substances into the U.S. market.

Given the regulatory landscape, Indian exporters aiming to penetrate the U.S. market must navigate these stringent controls. The presence of 59 active Indian exporters and a repeat buyer rate of 51.7% indicates a competitive market, necessitating strict adherence to FDA regulations to ensure market access and sustainability.

In the European Union (EU) and the United Kingdom (UK), ephedrine is classified as a controlled substance due to its potential for misuse. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) mandate that products containing ephedrine undergo rigorous evaluation to obtain marketing authorization. Compliance with Good Manufacturing Practice (GMP) standards is essential, ensuring that products meet the required quality, safety, and efficacy standards.

Indian exporters targeting these markets must ensure that their manufacturing processes align with EU and UK GMP requirements. This includes regular inspections and audits to verify compliance, thereby facilitating the approval process and market entry.

As of the 24th edition of the WHO Model List of Essential Medicines, updated in September 2025, ephedrine is not included. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, focusing on medicines that address priority health needs. (who.int)

Despite its exclusion from the WHO Model List, ephedrine must comply with international pharmacopoeia standards, including those set by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality and safety of ephedrine products in the global market.

In India, ephedrine is classified as a Schedule X drug under the Drugs and Cosmetics Act, indicating its high potential for abuse and stringent regulatory controls. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, as of March 2026, ephedrine is not listed under the Drugs (Prices Control) Order (DPCO), and thus, no ceiling price has been established.

For export purposes, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for the export of controlled substances like ephedrine. This ensures that exports comply with national regulations and international commitments to prevent misuse.

Ephedrine is a well-established pharmaceutical compound with no active patents or exclusivity rights, allowing for generic production and export. This has led to a competitive market with multiple manufacturers and exporters, as evidenced by the 59 active Indian exporters between 2022 and 2026.

In January 2025, the FDA updated Import Alert 54-13 to reinforce the detention without physical examination of dietary supplements and bulk dietary ingredients containing ephedrine alkaloids from all countries. This action underscores the FDA's ongoing efforts to prevent the entry of potentially harmful substances into the U.S. market.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the WHO Model List of Essential Medicines. The 24th edition, published in September 2025, did not include ephedrine, reflecting its current status in global health priorities. (who.int)

In February 2026, the NPPA conducted a review of the Drugs (Prices Control) Order (DPCO) list. Ephedrine was not added to the list, indicating that no ceiling price has been established for this compound as of March 2026.

These developments highlight the dynamic regulatory environment surrounding ephedrine, emphasizing the need for exporters to stay informed and compliant with international standards and regulations.

India's pharmaceutical industry, including the production of ephedrine, heavily relies on imports of Key Starting Materials (KSMs) and intermediates from China. China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the API sector. This dependency exposes Indian manufacturers to supply chain vulnerabilities, as any disruptions in Chinese exports can significantly impact production timelines and costs.

Recent geopolitical tensions have further exacerbated these risks. In June 2025, escalating conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical chokepoint for global energy and chemical shipments. This disruption affected the availability of petrochemical feedstocks essential for API synthesis, leading to increased production costs and potential delays in pharmaceutical manufacturing. (pharmasource.global)

Our proprietary trade data indicates that the top five Indian exporters of ephedrine account for 67.8% of total exports, with MANKIND PHARMA LIMITED alone contributing 20.2%. This high supplier concentration poses a significant risk, as any operational or compliance issues within these key companies could disrupt the global supply chain.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme aimed at boosting domestic API manufacturing and reducing reliance on imports. The scheme has led to increased investments in local production capacities, enhancing supply chain resilience. (pharmanow.live)

The closure of the Strait of Hormuz in early 2026 due to military conflicts has severely disrupted global supply chains. Approximately 20% of the world's oil and a significant portion of petrochemical feedstocks transit through this strait. The blockade has led to increased shipping costs, delays, and heightened risks for pharmaceutical supply chains, including the transportation of APIs like ephedrine.

Additionally, tensions in the Red Sea and the Suez Canal have further complicated shipping routes, forcing vessels to take longer paths around the Cape of Good Hope. This rerouting adds approximately 10 to 14 days to transit times, impacting the timely delivery of pharmaceutical products.

• Diversify Supplier Base: Engage with a broader range of API suppliers to reduce dependency on a limited number of manufacturers.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local API manufacturing facilities, reducing reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping disruptions, allowing for proactive adjustments to logistics strategies.

• Develop Alternative Shipping Routes: Explore and establish alternative shipping routes and logistics partners to mitigate risks associated with chokepoints like the Strait of Hormuz and the Suez Canal.

• Increase Inventory Buffers: Maintain higher inventory levels of critical APIs to cushion against potential supply chain disruptions.

RISK_LEVEL: HIGH